The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical
| Autor: | Xiaojing Zhao, Zhongna Yu, Xinrun Wang, Xiaojing Li, Yang Liu, Liang Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Gynecological Endocrinology, Vol 40, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 09513590 1473-0766 0951-3590 |
| DOI: | 10.1080/09513590.2024.2382818 |
| Popis: | Premature ovarian insufficiency (POI) or premature ovarian failure (POF) is a multifactorial disorder occurring in reproductive-age women, characterized by elevated levels of follicle-stimulating hormone (FSH) and irregular or absent menstrual cycles, often accompanied by perimenopausal symptoms and infertility. While assisted reproductive technology can address the reproductive aspirations of some POI-affected women, it is hindered by issues such as exorbitant expenses, substantial risks, and poor rates of conception. Encouragingly, extensive research is exploring novel approaches to enhance fertility, particularly in the realm of stem cell therapy, showcasing both feasibility and significant potential. Human amniotic epithelial cells (hAECs) from discarded placental tissues are crucial in regenerative medicine for their pluripotency, low immunogenicity, non-tumorigenicity, accessibility, and minimal ethical concerns. Preclinical studies highlight the underlying mechanisms and therapeutic effects of hAECs in POI treatment, and current research is focusing on innovative interventions to augment hAECs’ efficacy. However, despite these strides, overcoming application challenges is essential for successful clinical translation. This paper conducted a comprehensive analysis of the aforementioned issues, examining the prospects and challenges of hAECs in POI, with the aim of providing some insights for future research and clinical practice. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|